Hydroxytyrosol and Vitamin E in Pediatric NASH

• Status: Completed
• Trial end date: 2018-05-31
• Target enrollment: 0
• Participant gender: All

Summary

Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children. The pathogenesis of NAFLD is generally considered the result of a series of liver injuries, commonly referred as "multi-hit" hypothesis. Several studies suggest that inflammatory pathways and oxidative stress could be responsible of disease progression to non-alcoholic steatohepatitis (NASH).

Hydroxytyrosol is a simple phenolic compound naturally occurring in olive and olive oil with antioxidant properties. Some studies have demonstrated that hydroxytyrosol show several anti-inflammatory and anti-atherogenic activities, such as the inhibition of LDL oxidation and platelet aggregation.

Alpha tocopherol (Vitamin E) is the most studied anti-oxydant in pediatric NAFLD with conflicting results. It inhibits proinflammatory cytokine production and attenuates the release of profibrogenic agents and liver collagen.

The purpose of this interventional study is to evaluate the efficacy and tolerability of Hydroxytyrosol and Vitamin E in the treatment of children with biopsy-proven NASH.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bambino Gesù Hospital and Research Institute
• Treatments: 3,4-dihydroxyphenylethanol; alpha-Tocopherol; Phenylethyl Alcohol; Tocopherols; Tocotrienols; Vitamin E; Vitamins

Criteria

Inclusion Criteria:

• Liver biopsy consistent with diagnosis of NASH (liver biopsy performed in 3-6 months before enrollment)

• Hyperechogenicity of liver at ultrasound examination

• ALT levels range between normal and < 10 UNL

• INR < 1.3

• Albumin > 3 gr/dl.

• Total bilirubin < 2.5 mg/dl

• normal renal function

• normal cells blood count

• exclusion of other causes of chronic hepatopathies in children

• Written informed consent to participate in the Protocol by their parents or legal guardians of patients

Exclusion Criteria:

• alcohols or drugs abuse

• use of drugs known to induce steatosis or to affect body weight or carbohydrate metabolism

• autoimmune liver diseases, Wilson's disease, alpha-1-antitripsin deficiency, metabolic liver disease

• every clinical or psychiatric diseases interfering with experimentation according to investigator's evaluation

• finding of active liver disease due to other causes